Clinical Trials Browser

Melanoma × Naltrexone × Clear all

NCT05968690 2025-09-18

Naltrexone and Propranolol Combined With Immunotherapy

Phase 1 Recruiting

Melanoma, Skin Neoplasms

NCT01650350 2022-03-04

Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer

Phase 2 Terminated

7 enrolled 5 charts

DermatologicGenitourinary

Kidney Neoplasms, Melanoma, Prostatic Neoplasms